Córdoba, September 1st 2015. VivaCell Biotechnology España SL (Vivacell), a preclinical-stage pharmaceutical company developing new non-psychotropic cannabinoid compounds for the treatment of inflammatory and neurodegenerative diseases, is pleased to announce that it has entered into partnership with Emerald Health Pharmaceuticals Inc (Emerald), a Canadian-based company focused on developing pharmaceutical candidates from cannabinoid derivatives.
Under the agreement, Emerald has made a material investment into Vivacell and Mr. James Heppell, the Chairman of Emerald, has been appointed to the Vivacell Board of Directors. Additionally, Emerald has acquired Vivacell’s intellectual property relating to its Series VCE-004 compounds and the parties have entered into a Collaborative Research Agreement for the preclinical development of selected VCE-004 derivatives. Series VCE-004 is a unique collection of new cannabidiol derivatives, with promising preclinical results in the treatment of Multiple Sclerosis, Scleroderma and Metabolic Syndrome.
The importance of this Strategic Partnership to Vivacell is based upon the financial support that Emerald can provide to Vivacell for the further development of its pipeline and the proven expertise and success record of the Emerald executives in the pharmaceutical industry.
About VivaCell Biotechnology España, S.L.
VivaCell Biotechnology España SL is a privately held, preclinical-stage pharmaceutical company based in Córdoba, Spain. Vivacell is worldwide pioneer in the discovery and development of cannabidiol and cannabigerol new derivatives for the treatment of inflammatory and neurodegenerative diseases. For more information, please send an email to firstname.lastname@example.org.
About Emerald Health Pharmaceuticals, Inc.
Emerald Health Pharmaceuticals, Inc. is a life science company focused on developing pharmaceutical drug candidates from compounds derived from cannabinoids. For more information, please visit www.emerald.care or send an email to email@example.com.